<DOC>
	<DOC>NCT01083680</DOC>
	<brief_summary>The purpose of this study was intended to evaluate the long-term safety and effectiveness of adalimumab in participants with Crohn's disease (CD) who are treated as recommended in the product label.</brief_summary>
	<brief_title>Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine</brief_title>
	<detailed_description>This study was a 60-month prospective, multicenter, observational study of adalimumab in adult participants with CD who resided in Germany. Visits were scheduled every 3 months for the first year and every 6 months thereafter. Participants continued in the study for a maximum of 60 months or until discontinuation from adalimumab therapy.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Severe, active Crohn's Disease in patients with insufficient response to a complete and adequate therapy of glucocorticoid and/or immunosuppressive drug and/or hypersensitivity against such a therapy or in patients where such a therapy is contraindicated. Hypersensitivity against the drug or one of the other ingredients.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Routine clinical setting</keyword>
	<keyword>Long-term efficacy and safety</keyword>
	<keyword>Crohn's Disease</keyword>
	<keyword>Humira®</keyword>
	<keyword>Adalimumab</keyword>
</DOC>